Catalent Biologics’ development services leverage advanced technology and proven expertise to help clients meet their biologics development needs. Our development teams collaborate closely with our bioanalytical testing and manufacturing teams to ensure that processes and products are scalable to clinical and commercial scale.
Catalent’s cell line development technology, GPEx®, produces high-performance, highly stable, production cell lines in a wide variety of mammalian host cells. Whether you utilize our cell line development technology, or develop your cell lines in house, our process development services ensure consistent cGMP manufacturing performance and a reliable product supply.
Our formulation development services utilize advanced technology and equipment to ensure delivery of a stable product to the patient. Catalent’s expertise in biosimilar development and manufacturing can accelerate your biosimilar development using a comprehensive suite of analytical capabilities and proven GPEx® technology. Finally, our antibody drug conjugate (ADC) and bioconjugation technology, SMARTag®, enables site-specific, controlled drug-protein conjugations and uses only naturally occurring modifications to proteins requiring minimal cell-line engineering.